treatment

Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment

New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through…

1 week ago

Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting

New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through…

1 week ago

Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns 350,000 prize

A study published in Science reveals that a healthy gut microbiota can enhance the efficacy of immunotherapy used to treat…

2 weeks ago

U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If…

2 weeks ago

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE…

3 weeks ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

February 11, 2026 06:00 ET  | Source: Upstream Bio – Verekitug provided statistically significant and clinically meaningful reductions in annualized…

4 weeks ago

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet in the treatment of canine mast cell tumors

PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR…

4 weeks ago

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry validates condensate modulator…

1 month ago

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform February 03, 2026 13:08 ET  | Source:…

1 month ago

QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced…

1 month ago